NSAID petition
This article was originally published in The Tan Sheet
Executive Summary
FDA has not yet reached a decision on a citizen petition asking the agency to research a link between ibuprofen, Stevens Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Seven petitioners had asked FDA in a Feb. 1 filing to conduct an assessment of ibuprofen and SJS/TEN risk, to investigate whether manufacturers withheld safety information related to such risks, and to add warnings to Rx and OTC labeling. The petition "raises complex issues requiring extensive review and analysis," FDA explains in an Aug. 5 response. The agency notes it has already directed manufacturers to make labeling changes to ibuprofen and other NSAIDs to "include additional warnings regarding the risks of SJS and TEN" as requested in the petition (1"The Tan Sheet" June 20, 2005, p. 5)...
You may also be interested in...
Requested OTC NSAID Labeling Includes Cardiac Risk, Front Panel Changes
Manufacturers of over-the-counter non-steroidal anti-inflammatory drugs should prominently identify their products as NSAIDs on packaging, according to an FDA request
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.